Nick is a co-founder and CEO of Accunea Ltd, a medical device company with real time diagnostic monitoring products for organ transplantation.
Genesis has secured a trial of their enterprise solutions with UK-based network provider, Vodafone. The trial will be held at Vodafone’s campus in Newbury, UK commencing the 30 March 2020.
A quick reminder that our first investor pitching and networking evening of the year will take place at our King’s Cross office at 6.30pm on the evening of Wednesday, February 26th.
To help you understand a company in more detail, it’s important that you know about its background, founders, achievements and any press coverage it might be receiving.
Deliveroo, Just Eat, Uber Eats and all the other major competitors in this market offer no incentive for consumers to use their services. Supermeal, on the other hand, saves you money through cash-back rewards when you ...
Read MoreMany UK Patients are dying on waiting lists for kidney transplants, perhaps unnecessarily...
Read MoreAccunea’s organ transplant technology has resonated with investors, with £260k of their £400k round, raised in less than a week. A spin-out from Imperial College ...
Read MoreWe are delighted to announce that our first investor event of the year will take place at our King’s Cross office at 7pm on the evening of Wednesday, February 26th.
Read MoreFollowing the recent announcement that Chayora Holdings Limited (“Chayora”) and Telstra International (“Telstra”) had entered into a strategic partnership, several investors have asked about the implications of the deal.
Read MoreBiotech LIfT BioSciences has announced a further major investment into the company in its mission to develop the first curative and affordable cell therapy for all solid tumours. Investors in this latest round included ...
Read More